Dominant-negative SOX9 mutations in campomelic dysplasia

Hum Mutat. 2019 Dec;40(12):2344-2352. doi: 10.1002/humu.23888. Epub 2019 Aug 26.

Abstract

Campomelic dysplasia (CD) is an autosomal dominant, perinatal lethal skeletal dysplasia characterized by a small chest and short long bones with bowing of the lower extremities. CD is the result of heterozygosity for mutations in the gene encoding the chondrogenesis master regulator, SOX9. Loss-of-function mutations have been identified in most CD cases so it has been assumed that the disease results from haploinsufficiency for SOX9. Here, we identified distal truncating SOX9 mutations in four unrelated CD cases. The mutations all leave the dimerization and DNA-binding domains intact and cultured chondrocytes from three of the four cases synthesized truncated SOX9. Relative to CD resulting from haploinsufficiency, there was decreased transactivation activity toward a major transcriptional target, COL2A1, consistent with the mutations exerting a dominant-negative effect. For one of the cases, the phenotypic consequence was a very severe form of CD, with a pronounced effect on vertebral and limb development. The data identify a novel molecular mechanism of disease in CD in which the truncated protein leads to a distinct and more significant effect on SOX9 function.

Keywords: SOX9; bent bone dysplasia; campomelic dysplasia; dominant negative.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Campomelic Dysplasia / genetics*
  • Campomelic Dysplasia / metabolism
  • Cells, Cultured
  • Chondrocytes / cytology
  • Chondrocytes / metabolism
  • Collagen Type II / genetics
  • Exome Sequencing / methods*
  • Female
  • Haploinsufficiency
  • Humans
  • Pregnancy
  • Prenatal Diagnosis
  • SOX9 Transcription Factor / genetics*
  • SOX9 Transcription Factor / metabolism*
  • Sequence Deletion

Substances

  • COL2A1 protein, human
  • Collagen Type II
  • SOX9 Transcription Factor
  • SOX9 protein, human